Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
26 févr. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following March investor conferences: TD...
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
20 févr. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 févr. 2024 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 4 new employees with a grant...
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
26 janv. 2024 07h06 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European...
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
08 janv. 2024 09h00 HE
|
Apellis Pharmaceuticals, Inc.
Approximately $114 million in preliminary fourth quarter SYFOVRE® revenue as strong launch continuesApproximately $24 million in preliminary fourth quarter EMPAVELI® revenue WALTHAM, Mass., Jan. ...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 janv. 2024 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 2 new employees with a grant...
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on...
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
28 déc. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite...
Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
14 déc. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today an update on the ongoing review of its marketing authorization application (MAA) for...
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
11 déc. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNHMajority of patients remained transfusion free over the long termZero cases of meningococcal...